On June 6, 2023, the Centers for Medicare & Medicaid Services published two new ICD-10-PCS codes for CYTALUX® (pafolacianine) injection, in ovarian and lung cancer surgery for use beginning October 1, 2023.
The International Classification of Diseases, 10th Revision, Procedure Coding System (ICD-10-PCS) is a U.S. cataloging system for procedural codes that track various health interventions taken by medical professionals and was developed by the Centers for Medicare and Medicaid Services (CMS) in conjunction with 3M Health Information Management to track international morbidity and mortality statistics in a comparable way. ICD-10-PCS is used for inpatient hospital settings in the United States.
The availability of this new ICD-10 PCS code will help hospitals properly document the procedure for the patients and thus advance efforts to ensure their clinical management is appropriate.
About On Target Laboratories, Inc.
On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery. Their molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, is comprised of a near-infrared dye and a targeting molecule, or ligand, that binds to receptors overexpressed on cancer cells. The imaging agents illuminate the cancerous tissue, which may enable surgeons to detect more cancer that otherwise may have been left behind.
CYTALUX, the Company’s first product, received FDA approval of a New Drug Application for ovarian cancer in November 2021 and a supplemental New Drug Application for lung cancer in December 2022. CYTALUX targets the folate receptors commonly found on many cancers, binds to the cancerous tissue, and illuminates under near-infrared light. A single dose of the agent is administered via intravenous infusion prior to surgery and assists surgeons in visually identifying additional cancerous tissue to be removed during the operation. For more information visit www.ontargetlabs.com and www.cytalux.com.